Johnson & Johnson plans to divide its pharmaceuticals group into three areas -- one for pain, infectious disease, cardiovascular and primary care, the central nervous system and metabolism; a second for cancer research, biotechnology and immunology; and a third for virology -- each providing research and development on specific health targets. Executives told employees the change would improve synergy between the company's research efforts and commercial opportunities.

Full Story:

Related Summaries